Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398588 | 1.00 | CTSL (0.38) | CTSLCTSBCTSSCTSKMMP13 | |
| SCHEMBL1105531 | 0.89 | AAK1 (0.36) | CTSLCTSBCTSSCTSKAAK1 | |
| SCHEMBL13818592 | 0.89 | MEN1 (0.50) | CTSLCTSBCTSSCTSK | |
| SCHEMBL2873494 | 0.89 | ALB (0.43) | — | |
| SCHEMBL9925881 | 0.88 | TAS1R3 (0.41) | CTSLCTSBCTSS | |
| SCHEMBL403066 | 0.88 | TAS1R3 (0.41) | CTSLCTSBCTSS | |
| SCHEMBL1105583 | 0.87 | CTSB (0.43) | CTSB | |
| SCHEMBL4232381 | 0.85 | — | — | |
| SCHEMBL1105617 | 0.85 | CTSL (0.42) | CTSLCTSS | |
| SCHEMBL1105673 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003343-A1 | EZH2 INHIBITION IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCERS | Constellation Pharmaceuticals, Inc. (US) | 2022-06-01 | — | — | EP | claimed |
| WO-2021016409-A1 | EZH2 INHIBITION IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCERS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2021-01-28 | — | — | WO | claimed |
| EP-2029572-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-03-04 | — | — | EP | claimed |
| WO-2007143597-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | claimed |
| WO-2023125907-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| EP-4003343-A1 | EZH2 INHIBITION IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCERS | Constellation Pharmaceuticals, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3774782-A2 | ATF6 INHIBITORS AND USES THEREOF | Black Belt TX Ltd (GB) | 2021-02-17 | — | — | EP | disclosed |
| WO-2021016409-A1 | EZH2 INHIBITION IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCERS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2021-01-28 | — | — | WO | disclosed |
| US-9617256-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170088549-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2017-03-30 | — | — | US | disclosed |
| EP-3080103-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Biogen MA Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2170814-B1 | ANTIBACTERIAL AGENTS | ACHAOGEN INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| WO-2008035195-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE ACID PUMP INHIBITORS | RAQUALIA PHARMA INC. (JP) | 2008-03-27 | — | — | WO | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | UNIVERSITY OF WASHINGTON | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | CTSL 127/4885CTSB 259/4885CTSS 300/4885 |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | PDF, DDOST, MRPL21 | CTSL 32/4885CTSB 67/4885CTSS 99/4885 |
| US-20170088549-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | CTSL 160/4885CTSB 260/4885CTSS 313/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | CTSL 127/4885CTSB 259/4885CTSS 300/4885 |
| US-20060154988-A1 | Antibacterial agents | MRPL21, SI, PGLS | CTSL 127/4885CTSB 259/4885CTSS 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.